Exact Sciences (EXAS) Blood-Based Multi-Cancer Screening Test Data Looks Positive but Early - BofA
Tweet Send to a Friend
BofA Securities analyst Derik de Bruin reiterated a Buy rating and $111.00 price target on Exact Sciences (NASDAQ: EXAS) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
